AZ COMPLETES AGREEMENT WITH PERRIGO
December 15, 2015 10:16 ET
|
AstraZeneca PLC
ASTRAZENECA COMPLETES AGREEMENT WITH PERRIGO FOR RIGHTS TO ENTOCORT® IN THE US
AstraZeneca today announced that it has completed its agreement with Perrigo
Company plc for the divestment of US rights...
Discussions with Acerta Pharma BV
December 14, 2015 03:07 ET
|
AstraZeneca PLC
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN, INTO OR FROM ANY JURISDICTION
WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS
OF SUCH JURISDICTION. THIS ANNOUNCEMENT...
ASTRAZENECA PLC ANNOUNCES LATE-STAGE PIPELINE CONFERENCE CALL FOR INVESTORS AND ANALYSTS
December 02, 2015 02:00 ET
|
AstraZeneca PLC
AstraZeneca PLC ("AstraZeneca", "the Company") will today host a conference call
for investors and analysts. This will focus on key potential medicines within
the late-stage pipeline and will provide...
AZ enters agreement w/ Perrigo for Entocort in US
November 23, 2015 02:00 ET
|
AstraZeneca PLC
ASTRAZENECA ENTERS INTO AGREEMENT WITH PERRIGO FOR RIGHTS TO ENTOCORT® IN THE US
Divestment further sharpens focus on three main therapy areas
Agreement follows ex-US divestment of Entocort in...
AZD9291 Approved by the US FDA
November 13, 2015 10:21 ET
|
AstraZeneca PLC
TAGRISSO™ (AZD9291) APPROVED BY THE US FDA FOR patients with EGFR T790M mutation
-positive METASTATIC non-small cell lung cancer
One of fastest development programmes - from start of clinical trials...
ASTRAZENECA PRICES A $6 BILLION BOND ISSUE
November 11, 2015 02:30 ET
|
AstraZeneca PLC
AstraZeneca PLC announces that yesterday it conducted a global bond market
transaction by issuing a total of $6bn of notes. The proceeds of the issue will
be used to fund the previously announced...
3rd Quarter Results
November 10, 2015 02:40 ET
|
AstraZeneca PLC
5 November 2015
Year-To-Date and Q3 2015 Results
Financial Summary
YTD 2015 Q3 2015
$m % change $m % change
...
ASTRAZENECA STRENGTHENS CARDIOVASCULAR AND METABOLIC DISEASE PORTFOLIO WITH ACQUISITION OF ZS PHARMA
November 06, 2015 06:21 ET
|
AstraZeneca PLC
AstraZeneca to acquire ZS Pharma for $90 per share
Acquisition includes potential best-in-class hyperkalaemia treatment currently
under US FDA regulatory review
Acquisition expected to contribute...
Delårsrapport AstraZeneca PLC för de första nio månaderna och tredje kvartalet 2015
November 05, 2015 02:03 ET
|
AstraZeneca PLC
Utvecklingen i sammandrag
+----------------------+--------+------+---------++--------+------+-------+
| |Första nio månaderna 2015|| Tredje kvartalet 2015...
AstraZeneca PLC year-to-date and Q3 Results 2015
November 04, 2015 04:00 ET
|
AstraZeneca PLC
Tomorrow, Thursday, 5th November 2015, AstraZeneca PLC will release year-to-date
and Q3 results for 2015 at 07:00 GMT.
An analyst presentation of the year to date and Q3 results for 2015 will...